CASI News and Press, CASI Pharmaceuticals Inc. From 11/09/20

Image source: The Motley Fool. CASI Pharmaceuticals Inc (NASDAQ: CASI) Q3 2020 Earnings Call Nov 9, 2020 , 4:30 p.m. ET Operator Continue reading For further details see: CASI Pharmaceuticals Inc (CASI) Q3 2020 Earnings Call Transcript

CASI Pharmaceuticals (CASI): Q3 GAAP EPS of -$0.14 misses by $0.08.Revenue of $4.24M (+52.0% Y/Y) beats by $0.8M.Press Release For further details see: CASI Pharmaceuticals EPS misses by $0.08, beats on revenue

CASI Pharmaceuticals Announces Third Quarter 2020 Financial Results - EVOMELA Third Quarter 2020 Revenue Exceeds Expectations; Company Increasing EVOMELA Full-Year Revenue Guidance for 2020 - - Expands Pipeline with First-In-Class Anti-FcyRIIB Monoclonal Antibody with Potent...

CASI Pharmaceuticals To Report Third Quarter 2020 Financial Results And Host Conference Call November 9, 2020 PR Newswire ROCKVILLE, MD., and BEIJING, Nov. 5, 2020 ROCKVILLE, MD., and BEIJING , Nov. 5, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc....

CStone Pharma out-licensed global rights (ex-China) for two immuno-oncology assets to US-based EQRx in a $1.3 billion agreement. CASI Pharma in-licensed China rights to a novel antibody checkpoint receptor inhibitor from Sweden's BioInvent in a $95 million deal. Shanghai's Zai Lab...

Do Analysts Think These Are Penny Stocks To Buy Now? This has been one of the roughest weeks for penny stocks and blue chip stocks alike. The sheer force of this October sell-off is something we haven’t seen the likes of since March. In fact, if you look at the S&P 50...

Gainers: Scholar Rock (SRRK) +87%.Weidai (WEI) +60%.1847 Goedeker (GOED) +43%.Harley-Davidson (HOG) +27%.Synalloy (SYNL) +25%.Exact Sciences (EXAS) +22%.Harbor Custom Development (HCDI) +21%.TuanChe (TC) +20%.Unifi (UFI) +19%.CASI Pharmaceuticals (CASI) +18%.Losers: Cataba...

Gainers: Scholar Rock Holding (SRRK) +80%, Exact Sciences (EXAS) +18%, CHF Solutions (CHFS) +17%, CASI Pharmaceuticals (CASI) +13%, Prelude Therapeutics (PRLD) +8%.Losers: Catabasis Pharmaceuticals (CATB) -68%, Galera Therapeutics (GRTX)&...

BioInvent International ([[BOVNF]]) and CASI Pharmaceuticals ([[CASI]] +3.6%) have entered into an exclusive licensing agreement for the development and commercialization of novel anti-FcγRIIB antibody, BI-1206, in mainland China, Taiwan, Hong Kong and Macau.BioInvent wi...

BioInvent licenses anti-FcγRllB antibody BI-1206 to CASI Pharmaceuticals for Greater China region - CASI's pipeline expanded to include first-in-class monoclonal antibody developed to unlock anti-cancer immunity in liquid and solid tumors - Collaboration accelerates a...